Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Overview of attention for article published in Journal of Hematology & Oncology, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog

policy: 1 policy source
twitter: 13 X users

Citations

dimensions_citation: 64 Dimensions

Readers on

mendeley: 47 Mendeley

Summary News Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 1 blog post.

LCAR-B38M CAR-T cell therapy promising at 4-year follow-up for treatment of refractory multiple myeloma

Physician's Weekly, 21 Jul 2022

1. At a 4-year follow-up for relapsed or refractory multiple myeloma (RRMM) patients treated with LCAR-B38M CAR-T cell therapy…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.